A Phase 3 interventional study of Guardix and Seprafilm in Patient Under Going Colorectal and Stomach Cancer Surgery, sponsored by Gachon University Gil Medical Center. Completed at 1 site in Korea, Republic of. Open to participants aged 25 Years to 90 Years. Per ClinicalTrials.gov, last updated 2015-09-01.
Sponsored by Gachon University Gil Medical Center · Phase 3, Interventional, and Treatment
The purpose of the study is to evaluate the efficacy of Seprafilm and guardix in reducing the incidence of bowel obstruction and to evaluate the incidence of all serious adverse events (SAEs) associated with the use of Seprafilm and guardix occurring within 30 days postoperatively.
2,851 studies on the registry are indexed under Stomach Neoplasms; 863 are open to participants now.
This study's enrollment of 200 is above the median of 67 across 2,095 interventional studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Gachon University Gil Medical Center is the lead sponsor of 88 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
6g per body
Procedure: Guardix · Procedure: Seprafilm
1 sheet per body
Procedure: Guardix · Procedure: Seprafilm
Applying 6g of guardix during abdominal surgery
Also known as: Guardix, Sami pharmaceutical company, Seprafilm
Applying 1 sheet of seprafilm during abdominal surgery
ileus rate
Reducing the incidence of bowel obstruction following intestinal resection, and subsequently, reducing the number of re-operations
Time frame: within 60 days
adverse effect rate
Time frame: within 60 days
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gachon University Gil Medical Center